Optical Coherence Tomography Analysis of Cystoid Macular Edema in Retinal Dystrophy Treated with Oral Acetazolamide: Two Cases

Background

Enhanced S-cone syndrome (ESCS) is an autosomal recessive retinal dystrophy associated with a NR2E3 mutation, causing night blindness, decreased visual acuity, and visual field defects [1]. Clinically, ESCS is characterized by annular pigmentation along the vascular arcades and macular abnormalities [2]. Best vitelliform macular dystrophy (BVMD) is also an autosomal but dominant hereditary retinal dystrophy associated with the BEST1 gene, which affects central vision with a relatively good prognosis and presents macular egg yolk yellow lesions [3].

• References

• 1 Haider NB, Jacobson SG, Cideciyan AV. et al. Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate. Nat Genet 2000; 24: 127-131
• 2 Audo I, Michaelides M, Robson AG. et al. Phenotypic variation in enhanced S-cone syndrome. Invest Ophthalmol Vis Sci 2008; 49: 2082-2093
• 3 Mohler CW, Fine SL. Long-term evaluation of patients with Bestʼs vitelliform dystrophy. Ophthalmology 1981; 88: 688-692
• 4 Zhang Q, Small KW, Grossniklaus HE. Clinicopathologic findings in Best vitelliform macular dystrophy. Graefes Arch Clin Exp Ophthalmol 2011; 249: 745-751
• 5 Huang Q, Chen R, Lin X. et al. Efficacy of carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa: A meta-analysis. PLoS One 2017; 12: e0186180
• 6 Khairallah M, Ladjimi A, Ben Yahia S. et al. Elevated macular retinoschisis associated with Goldmann-Favre syndrome successfully treated with grid laser photocoagulation. Retina 2002; 22: 234-237
• 7 Iannaccone A, Fung KH, Eyestone ME. et al. Treatment of adult-onset acute macular retinoschisis in enhanced s-cone syndrome with oral acetazolamide. Am J Ophthalmol 2009; 147: 307-312.e2
• 8 Hori K, Ishida S, Inoue M. et al. Treatment of cystoid macular edema with oral acetazolamide in a patient with best vitelliform macular dystrophy. Retina 2004; 24: 481-482
• 9 Wolfensberger TJ, Dmitriev AV, Govardovskii VI. Inhibition of membrane-bound carbonic anhydrase decreases subretinal pH and volume. Doc Ophthalmol 1999; 97: 261-271
• 10 Siesky B, Harris A, Brizendine E. et al. Literature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flow. Surv Ophthalmol 2009; 54: 33-46